J.S. Elborn

35.5k total citations · 7 hit papers
593 papers, 21.1k citations indexed

About

J.S. Elborn is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Molecular Biology. According to data from OpenAlex, J.S. Elborn has authored 593 papers receiving a total of 21.1k indexed citations (citations by other indexed papers that have themselves been cited), including 477 papers in Pulmonary and Respiratory Medicine, 79 papers in Epidemiology and 64 papers in Molecular Biology. Recurrent topics in J.S. Elborn's work include Cystic Fibrosis Research Advances (402 papers), Neonatal Respiratory Health Research (120 papers) and Tracheal and airway disorders (82 papers). J.S. Elborn is often cited by papers focused on Cystic Fibrosis Research Advances (402 papers), Neonatal Respiratory Health Research (120 papers) and Tracheal and airway disorders (82 papers). J.S. Elborn collaborates with scholars based in United Kingdom, United States and Germany. J.S. Elborn's co-authors include Michael M. Tunney, Judy Bradley, Scott C. Bell, Madeleine Ennis, Patrick A. Flume, Félix Ratjen, Edward F. McKone, John E. Moore, Michael W. Konstan and Harry Heijerman and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

J.S. Elborn

574 papers receiving 20.7k citations

Hit Papers

A CFTR Potentiator in Patients with Cystic Fibrosis and t... 2011 2026 2016 2021 2011 2015 2016 2017 2012 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
    2011 1.5k citations Jane C. Davies, Scott C. Bell et al. New England Journal of Medicine profile →
  2. Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR
    2015 1.2k citations J.S. Elborn, Jane C. Davies et al. New England Journal of Medicine profile →
  3. Cystic fibrosis
    2016 1.1k citations J.S. Elborn profile →
  4. Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
    2017 553 citations Jennifer L. Taylor‐Cousar, À. Munck et al. New England Journal of Medicine profile →
  5. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
    2012 365 citations J.S. Elborn et al. profile →
  6. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety
    2015 280 citations J.S. Elborn et al. profile →
  7. Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis
    2017 247 citations James D. Chalmers, Kelly Moffitt et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.S. Elborn United Kingdom 68 15.2k 4.1k 2.8k 2.1k 1.3k 593 21.1k
Michael W. Konstan United States 71 15.2k 1.0× 2.5k 0.6× 2.2k 0.8× 2.2k 1.0× 644 0.5× 243 18.0k
Bonnie W. Ramsey United States 71 16.5k 1.1× 5.5k 1.3× 3.5k 1.2× 1.7k 0.8× 2.5k 2.0× 199 21.6k
Félix Ratjen Canada 65 14.9k 1.0× 2.5k 0.6× 2.2k 0.8× 2.8k 1.3× 798 0.6× 452 18.1k
Margaret Rosenfeld United States 61 13.1k 0.9× 2.1k 0.5× 2.5k 0.9× 2.3k 1.1× 717 0.6× 233 18.1k
Jane C. Davies United Kingdom 49 9.0k 0.6× 2.8k 0.7× 1.4k 0.5× 1.7k 0.8× 545 0.4× 353 12.8k
Frank J. Accurso United States 57 9.9k 0.7× 2.0k 0.5× 1.8k 0.6× 1.3k 0.6× 421 0.3× 191 12.5k
Bruce C. Marshall United States 52 10.0k 0.7× 1.5k 0.4× 2.5k 0.9× 943 0.5× 714 0.6× 138 13.2k
Nanshan Zhong China 58 7.0k 0.5× 2.4k 0.6× 1.9k 0.7× 4.0k 1.9× 401 0.3× 551 18.1k
Gerd Döring Germany 62 7.7k 0.5× 6.4k 1.6× 1.8k 0.6× 1.1k 0.5× 2.0k 1.6× 176 14.4k
Francesco Blasi Italy 61 6.3k 0.4× 1.1k 0.3× 7.2k 2.6× 2.4k 1.1× 684 0.5× 590 16.1k

Countries citing papers authored by J.S. Elborn

Since Specialization
Citations

This map shows the geographic impact of J.S. Elborn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.S. Elborn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.S. Elborn more than expected).

Fields of papers citing papers by J.S. Elborn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.S. Elborn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.S. Elborn. The network helps show where J.S. Elborn may publish in the future.

Co-authorship network of co-authors of J.S. Elborn

This figure shows the co-authorship network connecting the top 25 collaborators of J.S. Elborn. A scholar is included among the top collaborators of J.S. Elborn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.S. Elborn. J.S. Elborn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Donohue, James F., J.S. Elborn, Peter Lansberg, et al.. (2023). Bridging the “Know-Do” Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science. Journal of Healthcare Leadership. Volume 15. 103–119. 17 indexed citations
2.
Bradley, Judy, Kathryn M. Ferguson, Katherine O’Neill, et al.. (2022). Clinimetric Properties of Outcome Measures in Bronchiectasis. Annals of the American Thoracic Society. 20(5). 648–659. 2 indexed citations
3.
4.
Loebinger, Michael R., Eva Polverino, Francesco Blasi, et al.. (2019). Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). Pulmonary Pharmacology & Therapeutics. 58. 101834–101834. 7 indexed citations
5.
Gilpin, D.F., Kevin Gallagher, José A. Bengoechea, et al.. (2019). Electronic cigarette vapour increases virulence and inflammatory potential of respiratory pathogens. Respiratory Research. 20(1). 267–267. 39 indexed citations
6.
Abdolrasouli, Alireza, Johanna Rhodes, Ferry Hagen, et al.. (2018). Airway persistence by the emerging multi‐azole‐resistant Rasamsonia argillacea complex in cystic fibrosis. Mycoses. 61(9). 665–673. 14 indexed citations
7.
Chalmers, James D., Kelly Moffitt, Guillermo Suárez-Cuartín, et al.. (2017). Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 195(10). 1384–1393. 247 indexed citations breakdown →
8.
Taylor‐Cousar, Jennifer L., À. Munck, Edward F. McKone, et al.. (2017). Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. New England Journal of Medicine. 377(21). 2013–2023. 553 indexed citations breakdown →
9.
Reihill, James, Brian Walker, Robert A. Hamilton, et al.. (2016). Inhibition of Protease–Epithelial Sodium Channel Signaling Improves Mucociliary Function in Cystic Fibrosis Airways. American Journal of Respiratory and Critical Care Medicine. 194(6). 701–710. 46 indexed citations
10.
Rowan, Stephen, Judy Bradley, Ian Bradbury, et al.. (2014). Lung Clearance Index is a Repeatable and Sensitive Indicator of Radiological Changes in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 189(5). 586–592. 54 indexed citations
11.
Shyamsundar, Murali, Daniel F. McAuley, Rebecca J. Ingram, et al.. (2014). Keratinocyte Growth Factor Promotes Epithelial Survival and Resolution in a Human Model of Lung Injury. American Journal of Respiratory and Critical Care Medicine. 189(12). 1520–1529. 85 indexed citations
12.
Tunney, Michael M., G.G. Einarsson, Lan Wei, et al.. (2013). Lung Microbiota and Bacterial Abundance in Patients with Bronchiectasis when Clinically Stable and during Exacerbation. American Journal of Respiratory and Critical Care Medicine. 187(10). 1118–1126. 229 indexed citations
13.
Carson, Shannon S., Christopher H. Goss, Sanjay R. Patel, et al.. (2013). An Official American Thoracic Society Research Statement: Comparative Effectiveness Research in Pulmonary, Critical Care, and Sleep Medicine. American Journal of Respiratory and Critical Care Medicine. 188(10). 1253–1261. 38 indexed citations
14.
Fodor, Anthony A., Erich Klem, D.F. Gilpin, et al.. (2012). The Adult Cystic Fibrosis Airway Microbiota Is Stable over Time and Infection Type, and Highly Resilient to Antibiotic Treatment of Exacerbations. PLoS ONE. 7(9). e45001–e45001. 283 indexed citations
15.
Craig, Thelma, Martin Duffy, Murali Shyamsundar, et al.. (2010). A Randomized Clinical Trial of Hydroxymethylglutaryl– Coenzyme A Reductase Inhibition for Acute Lung Injury (The HARP Study). American Journal of Respiratory and Critical Care Medicine. 183(5). 620–626. 152 indexed citations
16.
Shyamsundar, Murali, Scott McKeown, Cecilia O’Kane, et al.. (2009). Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy Volunteers. American Journal of Respiratory and Critical Care Medicine. 179(12). 1107–1114. 194 indexed citations
17.
Tunney, Michael M., Tyler R. Field, T. Fintan Moriarty, et al.. (2008). Detection of Anaerobic Bacteria in High Numbers in Sputum from Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 177(9). 995–1001. 352 indexed citations
18.
Martin, Susan E., et al.. (2007). Flight assessment in patients with respiratory disease: hypoxic challenge testing vs. predictive equations. QJM. 100(6). 361–367. 28 indexed citations
19.
Moore, John E., Jiru Xu, B. Cherie Millar, Jo‐Maree Courtney, & J.S. Elborn. (2003). Development of a Gram-negative selective agar (GNSA) for the detection of Gram-negative microflora in sputa in patients with cystic fibrosis. Journal of Applied Microbiology. 95(1). 160–166. 5 indexed citations
20.
Nixon, Lisette, et al.. (1998). Circulating Immunoreactive Interleukin-6 in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 157(6). 1764–1769. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael W. Konstan Breakdown of academic impact, for papers by Bonnie W. Ramsey Breakdown of academic impact, for papers by Félix Ratjen Breakdown of academic impact, for papers by Margaret Rosenfeld Breakdown of academic impact, for papers by Jane C. Davies Breakdown of academic impact, for papers by Frank J. Accurso Breakdown of academic impact, for papers by Bruce C. Marshall Breakdown of academic impact, for papers by Nanshan Zhong Breakdown of academic impact, for papers by Gerd Döring Breakdown of academic impact, for papers by Francesco Blasi
Rankless by CCL
2026